

Table SII. Randomized controlled trials (RCTs) making a head to head comparison between 2 or more methotrexate (MTX) dosing regimens

Author, year Country	MTX groups	Patients n	MTX test-dose, use of folic acid and duration of therapy	Dose adjustment and number of patients stopped	Results		
					Week 12 or 13	Week 16	Other time-point
Chladek et al. 2002 (14) Czech Republic	Group 1: MTX ^{Weinstein} 7.5 mg/week	12	TD: not mentioned FA: not mentioned D: 13 weeks	No DA: fixed dose No stopped patients mentioned	PASI50: 66.7% Mean ΔPASI: 33.26% PASI50: 75%		
	Group 2: MTX ^{Weinstein} 15 mg/week	12			Mean ΔPASI 27.46% Mean ΔPASI: 55% Mean ΔPASI: 62% Mean ΔPASI: 42% Mean ΔPASI: 58%		
Chladek et al. 2005 (13) Czech republic	Group 1: MTX ^{Weinstein} 7.5 mg/week	12	TD: not mentioned FA: not mentioned D: 13 weeks	No DA: fixed dose No stopped patients mentioned			
	Group 2: MTX ^{Weinstein} 15 mg/week	12					
	Group 3: MTX 7.5 mg/week	7					
	Group 4: MTX 15 mg/week	10					
Dogra et al. 2012 (15) India	Group 1: MTX 10 mg	30 (25 analysed)	TD: not mentioned FA: 5 mg the day before and after MTX administration D: 12 weeks	No DA: fixed dose 3% (n=1) stopped due to AE	PASI75: 72% PASI100: 30%	Median time to achieve PASI75 (mean ± SD): 66.29 ± 16.03	
Radmanesh et al. 2011 (12) Bangladesh	Group 2: MTX 25 mg	30 (26 analysed)		No DA: fixed dose 10% (n=3) stopped due to AE	PASI75: 92% PASI100: 69%	Median time to achieve PASI75 (mean ± SD): 55.44 days ± 13.37	
	Group 1: MTX ^{Weinstein} 15 mg/week	147 (101 analysed)	TD: not mentioned FA: no folic acid allowed D: 4 months	No DA: fixed dose 6% (9/147) stopped due to AE No DA: fixed dose 3.5% (4/158) stopped due to AE		PASI25: 94% PASI75: 80% PASI25: 78% PASI75: 61%	
Group 2: MTX 2.5 mg 6 days/week	158 (101 analysed)						

i: intervention; N: number of patients in MTX-treated group; D: duration of therapy; TD: MTX test-dose; FA: use of folic acid; SD: standard deviation; ↑↓: increments; DA: dose adjustment.